Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Associated factors and effects of comorbid atrial fibrillation in hypertensive patients due to primary aldosteronism

Journal of Human Hypertension volumeĀ 37,Ā pages 757ā€“766 (2023)Cite this article

Subjects

Abstract

The incidence of atrial fibrillation (AF) and risk of cardiovascular events are reportedly higher in patients with primary aldosteronism (PA) than essential hypertension. However, associated factors of comorbid AF and cardiovascular events in PA patients after PA treatment remain unclear. This nationwide registration study included PA patients ā‰„20 years old. Incident cardiovascular events were observed with a mean follow-up of approximately 3 years. A total of 3654 patients with PA were included at the time of analysis. Prevalence of AF was 2.4%. PA patients with AF were older, more frequently male and had longer duration of hypertension than those without AF. No significant difference in basal plasma and adrenal venous aldosterone concentration, renin activity, potassium concentration, confirmatory tests of PA, laterality or surgery rate were seen between groups. Logistic regression analysis showed age, male sex, cardiothoracic ratio, past history of coronary artery disease and heart failure were independent factors associated with AF. PA patients with AF showed a higher frequency of cardiovascular events than those without AF (Pā€‰<ā€‰0.001). Multivariate Cox analyses demonstrated AF in addition to older age, duration of hypertension, body mass index and chronic kidney disease as independent prognostic factors for cardiovascular events after PA treatment. Incidence of cardiovascular events were significantly lower in PA patients with AF than AF patients from the Fushimi registry during follow-up after adjusting age, sex and systolic blood pressure. Early diagnosis of PA may prevent AF and other cardiovascular events in PA patients by shortening the duration of hypertension and appropriate PA treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The study flow chart shows final subtype diagnosis of primary aldosteronism was achieved by adrenal vein sampling in 4050 patients.
Fig. 2: Kaplanā€“Meier cumulative incidence curves for the composite end point of cardiovascular events including myocardial infarction, congestive heart failure, cerebral hemorrhage or cerebral infarction in the entire population.
Fig. 3: Kaplanā€“Meier cumulative incidence curves for the composite end point of cardiovascular events including myocardial infarction, congestive heart failure, cerebral hemorrhage or cerebral infarction in the entire population.

Similar content being viewed by others

References

  1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893ā€“962.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  2. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837ā€“47.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  3. Rienstra M, Lyass A, Murabito JM, Magnani JW, Lubitz SA, Massaro JM, et al. Reciprocal relations between physical disability, subjective health, and atrial fibrillation: the Framingham Heart Study. Am Heart J. 2013;166:171ā€“8.

    ArticleĀ  PubMedĀ  PubMed CentralĀ  Google ScholarĀ 

  4. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889ā€“916.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  5. Rossi GP. Primary aldosteronism: JACC state-of-the-art review. J Am Coll Cardiol. 2019;74:2799ā€“811.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  6. Monticone S, Dā€™Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6:41ā€“50.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  7. Umakoshi H, Tsuiki M, Takeda Y, Kurihara I, Itoh H, Katabami T, et al. Significance of computed tomography and serum Potassium in predicting subtype diagnosis of primary Aldosteronism. J Clin Endocrinol Metab. 2018;103:900ā€“8.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  8. Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y, et al. Prevalence of cardiovascular disease and its risk factors in primary Aldosteronism: a multicenter study in Japan. Hypertension. 2018;71:530ā€“7.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  9. Akehi Y, Yanase T, Motonaga R, Umakoshi H, Tsuiki M, Takeda Y, et al. High prevalence of diabetes in patients with primary Aldosteronism (PA) associated with subclinical hypercortisolism and prediabetes more prevalent in Bilateral than Unilateral PA: a large, multicenter cohort study in Japan. Diabetes Care. 2019;42:938ā€“45.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  10. Kobayashi H, Nakamura Y, Abe M, Kurihara I, Itoh H, Ichijo T, et al. Effect of cosyntropin during adrenal venous sampling on subtype of primary aldosteronism: analysis of surgical outcome. Eur J Endocrinol. 2020;182:265ā€“73.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  11. Ohno Y, Sone M, Inagaki N, Kawashima A, Takeda Y, Yoneda T, et al. Nadir Aldosterone levels after Confirmatory Tests are correlated with left ventricular hypertrophy in Primary Aldosteronism. Hypertension. 2020:HYPERTENSIONAHA11914601.

  12. Seccia TM, Caroccia B, Adler GK, Maiolino G, Cesari M, Rossi GP. Arterial hypertension, Atrial Fibrillation, and Hyperaldosteronism: the triple trouble. Hypertension. 2017;69:545ā€“50.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  13. Esato M, Chun YH, An Y, Ogawa H, Wada H, Hasegawa K, et al. Clinical impact of Asymptomatic presentation status in patients with Paroxysmal and Sustained Atrial Fibrillation: The Fushimi AF Registry. Chest. 2017;152:1266ā€“75.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  14. Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, et al. The Japanese Society of hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res. 2014;37:253ā€“390.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  15. Okamoto R, Taniguchi M, Onishi Y, Kumagai N, Uraki J, Fujimoto N, et al. Predictors of confirmatory test results for the diagnosis of primary hyperaldosteronism in hypertensive patients with an aldosterone-to-renin ratio greater than 20. The SHRIMP study. Hypertens Res. 2019;42:40ā€“51.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  16. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982ā€“92.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  17. Marwick TH, Gillebert TC, Aurigemma G, Chirinos J, Derumeaux G, Galderisi M, et al. Recommendations on the use of Echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). J Am Soc Echocardiogr. 2015;28:727ā€“54.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  18. Benjamin EJ, Levy D, Vaziri SM, Dā€™Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840ā€“4.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  19. Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM, Edvardsson N, et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study. Eur Heart J. 2013;34:1061ā€“7.

    ArticleĀ  PubMedĀ  PubMed CentralĀ  Google ScholarĀ 

  20. Chatterjee NA, Chae CU, Kim E, Moorthy MV, Conen D, Sandhu RK, et al. Modifiable Risk Factors for Incident Heart Failure in Atrial Fibrillation. JACC Heart Fail. 2017;5:552ā€“60.

    ArticleĀ  PubMedĀ  PubMed CentralĀ  Google ScholarĀ 

  21. Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol. 2017;69:1811ā€“20.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  22. Watson T, Karthikeyan VJ, Lip GY, Beevers DG. Atrial fibrillation in primary aldosteronism. J Renin Angiotensin Aldosterone Syst. 2009;10:190ā€“4.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  23. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension. 2003;41:218ā€“23.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  24. Vaziri SM, Larson MG, Lauer MS, Benjamin EJ, Levy D. Influence of blood pressure on left atrial size. The Framingham Heart Study. Hypertension. 1995;25:1155ā€“60.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  25. Reil JC, Hohl M, Selejan S, Lipp P, Drautz F, Kazakow A, et al. Aldosterone promotes atrial fibrillation. Eur Heart J. 2012;33:2098ā€“108.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  26. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832ā€“9.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  27. Alexandre J, Dolladille C, Douesnel L, Font J, Dabrowski R, Shavit L, et al. Effects of mineralocorticoid receptor antagonists on atrial fibrillation occurrence: a systematic review, meta-analysis, and meta-regression to identify modifying factors. J Am Heart Assoc. 2019;8:e013267.

    ArticleĀ  PubMedĀ  PubMed CentralĀ  Google ScholarĀ 

  28. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243ā€“8.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  29. Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013;62:331ā€“6.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  30. Badheka AO, Patel NJ, Grover PM, Shah N, Patel N, Singh V, et al. Optimal blood pressure in patients with atrial fibrillation (from the AFFIRM Trial). Am J Cardiol. 2014;114:727ā€“36.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  31. Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, et al. Observational study mortality in treated primary aldosteronism: the German Connā€™s registry. Hypertension. 2012;60:618ā€“24.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  32. Rossi GP, Maiolino G, Flego A, Belfiore A, Bernini G, Fabris B, et al. Adrenalectomy lowers incident Atrial Fibrillation in Primary Aldosteronism patients at long term. Hypertension. 2018;71:585ā€“91.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  33. Pan CT, Liao CW, Tsai CH, Chen ZW, Chen L, Hung CS, et al. Influence of different treatment strategies on New-Onset Atrial Fibrillation among patients with Primary Aldosteronism: a Nationwide Longitudinal Cohort-Based Study. J Am Heart Assoc. 2020;9:e013699.

    ArticleĀ  CASĀ  PubMedĀ  PubMed CentralĀ  Google ScholarĀ 

Download references

Acknowledgements

We wish to thank the JPAS/JRAS study members for collecting the clinical data. We are grateful to Keiko Umegaki (Kyoto Medical Center) and Kazuho Ikedo (Mie University) for their excellent technical assistance and the Fushimi AF registry investigators for their great help in revising this paper.

Funding

This work was supported by the Japan Agency for Medical Research and Development (AMED) (grant numbers JP17ek0109112 and JP20ek0109352 to MN), Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Technology, Sports and Culture, Japan, and the Mie Medical Foundation (grant number 19K08578 to RO and KD) and the National International Center for Health and Global Medicine, Japan (grant number 30ā€“1008 to AT).

Author information

Authors and Affiliations

  1. Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan

    Shintaro Sakaguchi,Ā Ryuji Okamoto,Ā Satoshi FujitaĀ &Ā Kaoru Dohi

  2. Department of Cardiology, Matsusaka Municipal Hospital, Matsusaka, Japan

    Shintaro Sakaguchi

  3. Department of Diabetes, Metabolism and Endocrinology, Mie University Graduate School of Medicine, Tsu, Japan

    Chisa InoueĀ &Ā Yutaka Yano

  4. Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan

    Masaharu Akao

  5. Department of Cardiology, Shinko Hospital, Kobe, Japan

    Kohei Kamemura

  6. Department of Endocrinology, Metabolism, and Nephrology, Keio University School of Medicine, Tokyo, Japan

    Isao KuriharaĀ &Ā Hiroshi Itoh

  7. Department of Internal Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan

    Yoshiyu Takeda

  8. Department of Diabetes, Endocrinology and Nutrition, Kyoto University, Kyoto, Japan

    Youichi OhnoĀ &Ā Nobuya Inagaki

  9. Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

    Hiromi RakugiĀ &Ā Koichi Yamamoto

  10. Division of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine Yokohama City Seibu Hospital, Yokohama, Japan

    Takuyuki Katabami

  11. Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center and Endocrine Center, Kyoto, Japan

    Mika TsuikiĀ &Ā Mitsuhide Naruse

  12. Division of Endocrinology, National Center for Global Health and Medicine, Tokyo, Japan

    Akiyo Tanabe

  13. Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    Kouichi Tamura

  14. Endocrine Center, Ijinkai Takeda General Hospital, Kyoto, Japan

    Mitsuhide Naruse

  15. Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan

    Masanori AbeĀ &Ā Hiroki Kobayashi

  16. Endovascular Treatment Group, Mito Saiseikai General Hospital, Mito, Japan

    Yoshiro Chiba

  17. Department of Cardiology, JR Hiroshima Hospital, Hiroshima, Japan

    Yuichi Fujii

  18. Division of Nephrology and Endocrinology, University of Tokyo, Tokyo, Japan

    Megumi Fujita

  19. Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

    Michiaki Fukui

  20. Department of Internal Medicine, Matsuyama Red Cross Hospital, Matsuyama, Japan

    Tomikazu Fukuoka

  21. Departments of Metabolism & Endocrinology, Juntendo University, Graduate School of Medicine, Tokyo, Japan

    Hiromasa Goto

  22. Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan

    Tomonobu Hasegawa

  23. Department of Internal Medicine III, Fukushima Medical University School of Medicine, Fukushima, Japan

    Shigeatsu Hashimoto

  24. Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    Tatsuya Haze

  25. Department of Endocrinology and Metabolism, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan

    Takamasa Ichijo

  26. Division of Nephrology and Hypertension, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan

    Tamio Iwamoto

  27. Division of Endocrinology and Metabolism, Tottori University Faculty of Medicine, Yonago, Japan

    Shoichiro Izawa

  28. Department of Cardiology, Saiseikai Tondabayashi Hospital, Tondabayashi, Japan

    Tatsuya Kai

  29. Center for Genomic Medicine, Kyoto University, Kyoto, Japan

    Takahisa KawaguchiĀ &Ā Fumihiko Matsuda

  30. Department of Preventive Services, Kyoto University School of Public Health, Kyoto, Japan

    Takashi Kawamura

  31. Department of Metabolic Medicine, Faculty of Life Science, Kumamoto University, Kumamoto, Japan

    Junji Kawashima

  32. Department of Clinical Research Pathology Division, National Hospital Organization Hakodate Hospital, Hakodate, Japan

    Noriko Kimura

  33. Department of Cardiology, Sanda City Hospital, Sanda, Japan

    Yuichi Matsuda

  34. Department of Internal Medicine, Uwajima City Hospital, Uwajima, Japan

    Shozo Miyauchi

  35. Division of Pathology, Tohoku Medical and Pharmaceutical University, Sendai, Japan

    Yoshihiro Nakamura

  36. Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan

    Koshiro Nishimoto

  37. Department of Urology, Kyoto University, Kyoto, Japan

    Osamu OgawaĀ &Ā Toshinari Yamasaki

  38. Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    Yoshihiro OgawaĀ &Ā Ryuichi Sakamoto

  39. Clinical Research Institute, National Hospital Organization Kyusyu Medical Center, Fukuoka, Japan

    Atsushi Ogo

  40. Department of Endocrinology, Tenri Hospital, Tenri, Japan

    Shintaro Okamura

  41. Department of Endocrinology and Diabetes, Tokai Central Hospital, Tokai, Japan

    Ataru Okumura

  42. Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita, Japan

    Michio Otsuki

  43. Department of Clinical Research and Informatics, Research Institute, International Medical Center, Tokyo, Japan

    Takuro Shimbo

  44. Division of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan

    Masakatsu Sone

  45. Division of Endocrinology and Metabolism, Japanese Red Cross Musashino Hospital, Tokyo, Japan

    Toru Sugiyama

  46. Department of Endocrinology, Diabetes and Metabolism, Fujita Health University, Toyoake, Japan

    Atsushi Suzuki

  47. Department of Public Health, International University of Health and Welfare School of Medicine, Narita, Japan

    Tomoko Suzuki

  48. Division of Metabolism, Showa General Hospital, Kodaira, Japan

    Katsutoshi Takahashi

  49. Department of Healthcare Economics and Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

    Tomoyuki Takura

  50. Department of Human Genetics and Disease Diversity, Tokyo Medical and Dental University, Tokyo, Japan

    Toshihiro Tanaka

  51. Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan

    Norio Wada

  52. Department of Endocrinology and Diabetes, Okazaki City Hospital, Okazaki, Japan

    Minemori Watanabe

  53. Department of Metabolism and Endocrinology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan

    Tetsuhiro Watanabe

  54. Division of Endocrinology and Metabolism, Department of Internal Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan

    Masanobu Yamada

  55. Department of Endocrinology and Diabetes Mellitus, Faculty of Medicine, Fukuoka University, Fukuoka, Japan

    Toshihiko Yanase

  56. Department of Health Promotion and Medicine of the Future, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan

    Takashi Yoneda

  57. Department of Endocrinology and Diabetes Mellitus, Misato Kenwa Hospital, Misato, Japan

    Yuichiro Yoshikawa

  58. Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

    Takanobu Yoshimoto

Authors
  1. Shintaro Sakaguchi
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  2. Ryuji Okamoto
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  3. Chisa Inoue
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  4. Masaharu Akao
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  5. Kohei Kamemura
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  6. Isao Kurihara
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  7. Yoshiyu Takeda
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  8. Youichi Ohno
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  9. Nobuya Inagaki
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  10. Hiromi Rakugi
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  11. Takuyuki Katabami
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  12. Mika Tsuiki
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  13. Akiyo Tanabe
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  14. Kouichi Tamura
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  15. Satoshi Fujita
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  16. Yutaka Yano
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  17. Kaoru Dohi
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  18. Mitsuhide Naruse
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

Consortia

JRAS investigators

  • Masanori Abe
  • ,Ā Yoshiro Chiba
  • ,Ā Yuichi Fujii
  • ,Ā Megumi Fujita
  • ,Ā Michiaki Fukui
  • ,Ā Tomikazu Fukuoka
  • ,Ā Hiromasa Goto
  • ,Ā Tomonobu Hasegawa
  • ,Ā Shigeatsu Hashimoto
  • ,Ā Tatsuya Haze
  • ,Ā Takamasa Ichijo
  • ,Ā Hiroshi Itoh
  • ,Ā Tamio Iwamoto
  • ,Ā Shoichiro Izawa
  • ,Ā Tatsuya Kai
  • ,Ā Takahisa Kawaguchi
  • ,Ā Takashi Kawamura
  • ,Ā Junji Kawashima
  • ,Ā Noriko Kimura
  • ,Ā Hiroki Kobayashi
  • ,Ā Fumihiko Matsuda
  • ,Ā Yuichi Matsuda
  • ,Ā Shozo Miyauchi
  • ,Ā Yoshihiro Nakamura
  • ,Ā Koshiro Nishimoto
  • ,Ā Osamu Ogawa
  • ,Ā Yoshihiro Ogawa
  • ,Ā Atsushi Ogo
  • ,Ā Shintaro Okamura
  • ,Ā Ataru Okumura
  • ,Ā Michio Otsuki
  • ,Ā Ryuichi Sakamoto
  • ,Ā Takuro Shimbo
  • ,Ā Masakatsu Sone
  • ,Ā Toru Sugiyama
  • ,Ā Atsushi Suzuki
  • ,Ā Tomoko Suzuki
  • ,Ā Katsutoshi Takahashi
  • ,Ā Tomoyuki Takura
  • ,Ā Toshihiro Tanaka
  • ,Ā Norio Wada
  • ,Ā Minemori Watanabe
  • ,Ā Tetsuhiro Watanabe
  • ,Ā Masanobu Yamada
  • ,Ā Koichi Yamamoto
  • ,Ā Toshinari Yamasaki
  • ,Ā Toshihiko Yanase
  • ,Ā Takashi Yoneda
  • ,Ā Yuichiro Yoshikawa
  • ,Ā Takanobu Yoshimoto
  • Ā &Ā Mitsuhide Naruse

Contributions

RO and SS designed this study and carried out the analyses; RO, SS and MN drafted and revised the manuscript; and CI, MA, KK, IK, YT, YO, TK, MT, SF collected the data; NI, HR, AT, KT, YY, KD managed and advised for the study and the manuscript.

Corresponding author

Correspondence to Ryuji Okamoto.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisherā€™s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sakaguchi, S., Okamoto, R., Inoue, C. et al. Associated factors and effects of comorbid atrial fibrillation in hypertensive patients due to primary aldosteronism. J Hum Hypertens 37, 757ā€“766 (2023). https://doi.org/10.1038/s41371-022-00753-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41371-022-00753-2

Search

Advanced search

Quick links